Global Mammalian CDMO Service Market Growth (Status and Outlook) 2024-2030

Global Mammalian CDMO Service Market Growth (Status and Outlook) 2024-2030

The global Mammalian CDMO Service market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Mammalian CDMO Service Industry Forecast” looks at past sales and reviews total world Mammalian CDMO Service sales in 2022, providing a comprehensive analysis by region and market sector of projected Mammalian CDMO Service sales for 2023 through 2029. With Mammalian CDMO Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mammalian CDMO Service industry.

This Insight Report provides a comprehensive analysis of the global Mammalian CDMO Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Mammalian CDMO Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Mammalian CDMO Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mammalian CDMO Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mammalian CDMO Service.

United States market for Mammalian CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Mammalian CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Mammalian CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Mammalian CDMO Service players cover Cytovance Biologics, 3P Bio, AGC Biologics, KBI Biopharma, GTP Bioways, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Mammalian CDMO Service market by product type, application, key players and key regions and countries.

Segmentation by Type:
Cell Line Development
Genomic Analysis
Process Development
Analytical Services
Formulation Development
Manufacturing
Others

Segmentation by Application:
Contract Research Organizations (CROs)
Pharmaceutical
Biotechnology Companies
Government Agencies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Cell Line Development
Genomic Analysis
Process Development
Analytical Services
Formulation Development
Manufacturing
Others

Segmentation by Application:
Contract Research Organizations (CROs)
Pharmaceutical
Biotechnology Companies
Government Agencies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Cytovance Biologics
3P Bio
AGC Biologics
KBI Biopharma
GTP Bioways
Tanvex CDMO
Samsung Biologics
WuXi Biologics
PlantForm Corporation
Gedeon Richter
Lonza
Novartis
Rentschler Biopharma SE
Northway Biotech
Boehringer Ingelheim
Cambrex
FUJIFILM Diosynth Biotechnologies
GBI
Scorpius BioManufacturing

Please note: The report will take approximately 2 business days to prepare and deliver.